|
Outcomes of therapeutic plasma exchange: A 15-year tertiary center experience
Salwa Hindawi1, Osman Radhwi2, Maha Badawi1, Hanaa Rajab3, Fatma Al Mansouri4, Ali Alzahrani5, Hussam Bukhari6, Kholoud Gholam7, Ahmad Almalki7, Abdulaziz Awadh7, Ismat Khalil Yagoub7, Galila Zaher1
1 Department of Hematology, Faculty of Medicine, King Abdulaziz University; King Fahd Medical Research Center, Member of the Hematology Research Unit, King Abdulaziz University; Blood Transfusion Services Unit, King Abdulaziz University Hospital, Jeddah, Saudi Arabia
2 Department of Hematology, Faculty of Medicine, King Abdulaziz University; King Fahd Medical Research Center, Member of the Hematology Research Unit, King Abdulaziz University, Jeddah, Saudi Arabia
3 Hematology Division, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia
4 Department of Anesthesia, King Abdullah Medical Complex, Jeddah, Saudi Arabia
5 Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
6 Department of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
7 Blood Transfusion Services Unit, King Abdulaziz University Hospital, Jeddah, Saudi Arabia
Correspondence Address:
Osman Radhwi,
King Abdulaziz University, P.O. Box: 80200, Jeddah
Saudi Arabia
 Source of Support: None, Conflict of Interest: None DOI: 10.4103/ijh.ijh_2_23
|
|
BACKGROUND: Therapeutic plasma exchange (TPE) is a treatment option used in many medical conditions. Response rates are variable as some disorders clearly benefit from TPE as first- or second-line therapy. This study aims to summarize our experience at King Abdulaziz University Hospital at King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
MATERIALS AND METHODS: In a retrospective fashion, wdemographic data, underlying disease, apheresis-related parameters, and outcomes were collected.
RESULTS: Between January 2005 and March 2020, 159 patients with 177 episodes underwent a total of 945 sessions of TPE. The majority of patients (96.8%) undergoing TPE in our center are of categories I to III according to 2019 American Society for Apheresis guidelines. Most patients had neurologic disorders, 74 (46.5%), where myasthenia gravis was the most common indication, 34 (21.4%) patients with response in 44/45 (97.8%) episodes, followed by thrombotic microangiopathies 31 (17.5%) patients with response in 17/34 (50%) episodes, Guillain–Barré syndrome 27 (16.9%) patients with recovery in 20/27 (74.1%) patients, and systemic lupus erythematous 25 (15.7%) patients with recovery in only 11/25 (44%) patients. Complications included hypotension in 29/945 (3.06%) sessions and citrate-induced symptoms in 6/945 (0.6%) sessions.
CONCLUSION: Our center complies with the recommended standards of indications for initiating TPE. Neurologic conditions constitute the largest group of patients requiring TPE.
|
Search Pubmed for